EMJ GOLD’s Post

By 2035, the American Heart Association (AHA) projects that the cost of treating heart disease—which, by then, would affect some 45 percent of the American population—could exceed $1 trillion. Research has cited how improved operational efficiency through monitoring technology can not only boost diagnostic accuracy and speed, but do so as cost effectively as routine care. Learn how in this #ClinicalView article. #PatientMonitoring

Valvular heart disease treatment has made impressive progress over the last two decades - yet not everyone is experiencing the benefits, even with new FDA guidance aimed at increasing diversity in clinical trials. For DCRI's Sreekanth Vemulapalli, one of the key areas that needs improvement is increase the diversity of patients at the beginning of the care pathway, but finding that exact time can be tricky: https://lnkd.in/eX4Cvydm #clinicaltrials #clinicalresearch #heartdisease #healthequity

𝗤𝘂𝗲𝘀𝘁𝗶𝗼𝗻 𝗼𝗳 𝗧𝗵𝗲 𝗪𝗲𝗲𝗸: “Which approach will more significantly impact resmetirom treatment: using NITs to identify Advanced NASH patients or continuing therapy until disease progression?” ANSWER HERE: https://lnkd.in/eiq4AF4g #surfingmash #QuestionOfTheWeek #resmetirom #NITs

The potential benefit of aspirin with Colorectal cancer risk ... Check our MedCentral coverage here - Aspirin Could Reduce Colorectal Cancer Risk in People with Less Healthy Lifestyles (medcentral.com)

Aspirin or No Aspirin; the recommendations 20+ years back versus present status as per recent research findings. Are we becoming more focused towards using/not using it as primary preventive measure in cardio-vascular disease? #patientcare #medicalresearch #medicalscience

We've collaborated with Breakthrough T1D (formerly JDRF), along with other key experts to develop international consensus guidance for monitoring persons with islet autoantibody-positive pre-stage 3 Type 1 diabetes. This new expert clinical advice highlights the importance of accurately diagnosing the current stage of T1D and providing ongoing monitoring for disease progression tailored to the needs of the affected individuals and their families. View the consensus here: https://bit.ly/3XMPGA9

In our latest article, we examine the controversial theory that microclots may be responsible for the persistent symptoms of #LongCovid. As researchers propose new treatments and patients seek desperate measures, we explore the evidence, the risks, and the urgent need for answers:

Through this case report of an older gentleman with new-onset diabetes and a normal BMI, we discuss how healthcare professionals can identify people who might be at risk of #PancreaticCancer, along with the differential diagnoses, and what actions they should take. Read more here: https://lnkd.in/dUQTJpj4

In the realm of medical challenges, many rare diseases, such as Barth syndrome—a rare and often unrecoverable diagnosis—takes families on an arduous journey. However, there's potential for transformative change with swift access to innovative treatments, bringing hope to those navigating the complexities of rare diseases. There's an urgent need for a paradigm shift in FDA review processes, recognizing the unique struggles of rare diseases. With the fate of patients living with rare diseases hanging in the balance, swift yet thorough drug approval could pave the way for broader access, offering a lifeline to countless individuals, turning exceptional stories into a beacon of possibility for all individuals facing these rare conditions. #RareDiseases #DrugDevelopment #DrugApproval

Heart failure is a complex, progressive condition. For too long, patients have faced challenges accessing life-saving therapies like LVADs at the right time in their care journey—often leading to outcomes that don’t fully reflect the potential of modern treatments. That’s why this trial is so important. TEAM-HF aims to set a new standard in how we identify patients at high risk of developing end-stage heart failure. Using remote pulmonary artery pressure (PAP) monitoring, we’re working to take the guesswork out of decision-making to help providers identify those who could benefit from an LVAD earlier in the disease spectrum, potentially improving survival and quality of life. Learn more about our approach: https://lnkd.in/gihngDGH US Safety Info: https://bit.ly/HM3_ISW https://bit.ly/CMEMS-ISI #ClinicalTrial #HeartFailure #LVAD